Omeros corporation reports updated results from narsoplimab hsct-tma clinical trial and highlights from recent clinical and cmc meetings with fda

Seattle--(business wire)--omeros corporation (nasdaq: omer) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma), markedly exceeding the fda-agreed threshold for the primary efficacy endpoint. while an overview of preliminary data submitted to fda was made public on december 4, 2019 in a press release from the company, all patients have now completed treatment and tr
OMER Ratings Summary
OMER Quant Ranking